论文部分内容阅读
脑脊液髓鞘碱性蛋白(MBP)自身抗体固相发光免疫分析法,是一项免疫检测新技术,目前国外尚未见到对脱髓病研究的报道。本文作者于1988.5～1989.3首先采用本法并证实其可靠性后,进入临床研究,对36例脱髓鞘病及20例其他CNS疾病者的对照组,用三项免疫指标行对比分析。CSFMBP自身抗体含量及其和同量IgG自身抗体的百分比值分别为69.23±11.95ng/ml及3.24±0.52ug/mg±gG和对照组相比,P值分别为<0.05及<0.001,有显著差异,对本病诊断有意义。
Cerebrospinal fluid myelin basic protein (MBP) autoantibodies solid-phase luminescence immunoassay, is a new immunoassay technology, so far no reports of demyelination research. The authors first entered the clinical study after confirming the reliability of this method from 1988.5 to 1989.3 and compared them with the control group of 36 patients with demyelinating disease and 20 patients with other CNS diseases by using three immune indexes. CSFMBP autoantibodies and the same amount of IgG autoantibodies were 69.23 ± 11.95ng / ml and 3.24 ± 0.52ug / mg ± gG, respectively, the P values were <0.05 and <0.001, respectively, with significant difference Difference, the diagnosis of this disease is meaningful.